nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—S100A2—exocrine gland—uterine cancer	0.0394	0.0835	CbGeAlD
Olopatadine—S100A1—exocrine gland—uterine cancer	0.0363	0.0769	CbGeAlD
Olopatadine—S100B—artery—uterine cancer	0.0359	0.0762	CbGeAlD
Olopatadine—S100A12—myometrium—uterine cancer	0.0176	0.0373	CbGeAlD
Olopatadine—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0175	0.463	CbGbCtD
Olopatadine—S100A2—epithelium—uterine cancer	0.0171	0.0363	CbGeAlD
Olopatadine—S100A2—uterine cervix—uterine cancer	0.017	0.036	CbGeAlD
Olopatadine—S100A2—renal system—uterine cancer	0.0159	0.0337	CbGeAlD
Olopatadine—S100A1—decidua—uterine cancer	0.0149	0.0316	CbGeAlD
Olopatadine—S100A2—mammalian vulva—uterine cancer	0.0149	0.0315	CbGeAlD
Olopatadine—S100A1—renal system—uterine cancer	0.0146	0.031	CbGeAlD
Olopatadine—S100A1—endometrium—uterine cancer	0.0141	0.03	CbGeAlD
Olopatadine—S100A13—epithelium—uterine cancer	0.014	0.0297	CbGeAlD
Olopatadine—S100A12—epithelium—uterine cancer	0.0138	0.0293	CbGeAlD
Olopatadine—S100A12—uterine cervix—uterine cancer	0.0137	0.029	CbGeAlD
Olopatadine—S100A13—smooth muscle tissue—uterine cancer	0.0135	0.0286	CbGeAlD
Olopatadine—S100A12—decidua—uterine cancer	0.013	0.0277	CbGeAlD
Olopatadine—S100A13—renal system—uterine cancer	0.013	0.0275	CbGeAlD
Olopatadine—S100A2—female reproductive system—uterine cancer	0.0127	0.027	CbGeAlD
Olopatadine—S100A12—mammalian vulva—uterine cancer	0.012	0.0254	CbGeAlD
Olopatadine—S100A1—female reproductive system—uterine cancer	0.0117	0.0248	CbGeAlD
Olopatadine—CYP3A4—Progesterone—uterine cancer	0.0116	0.307	CbGbCtD
Olopatadine—S100A2—female gonad—uterine cancer	0.0116	0.0245	CbGeAlD
Olopatadine—S100A2—vagina—uterine cancer	0.0115	0.0244	CbGeAlD
Olopatadine—S100A2—p73 transcription factor network—RNF43—uterine cancer	0.0113	0.126	CbGpPWpGaD
Olopatadine—S100A13—female reproductive system—uterine cancer	0.0104	0.022	CbGeAlD
Olopatadine—S100A13—female gonad—uterine cancer	0.00946	0.0201	CbGeAlD
Olopatadine—S100A12—female gonad—uterine cancer	0.00933	0.0198	CbGeAlD
Olopatadine—S100A12—vagina—uterine cancer	0.00928	0.0197	CbGeAlD
Olopatadine—S100A2—Direct p53 effectors—PMS2—uterine cancer	0.00771	0.0857	CbGpPWpGaD
Olopatadine—S100A1—lymph node—uterine cancer	0.00685	0.0145	CbGeAlD
Olopatadine—S100A13—lymph node—uterine cancer	0.00608	0.0129	CbGeAlD
Olopatadine—S100A12—lymph node—uterine cancer	0.006	0.0127	CbGeAlD
Olopatadine—S100B—lymph node—uterine cancer	0.00592	0.0126	CbGeAlD
Olopatadine—CYP3A4—Etoposide—uterine cancer	0.00519	0.137	CbGbCtD
Olopatadine—S100A2—Direct p53 effectors—MSH2—uterine cancer	0.00518	0.0576	CbGpPWpGaD
Olopatadine—S100A2—Direct p53 effectors—MLH1—uterine cancer	0.00467	0.0519	CbGpPWpGaD
Olopatadine—S100B—Nuclear signaling by ERBB4—PGR—uterine cancer	0.00413	0.0459	CbGpPWpGaD
Olopatadine—S100A2—Validated transcriptional targets of TAp63 isoforms—CDKN2A—uterine cancer	0.00389	0.0432	CbGpPWpGaD
Olopatadine—HRH1—myometrium—uterine cancer	0.00356	0.00755	CbGeAlD
Olopatadine—CYP3A4—Doxorubicin—uterine cancer	0.00354	0.0936	CbGbCtD
Olopatadine—S100A2—Validated transcriptional targets of TAp63 isoforms—EP300—uterine cancer	0.00303	0.0336	CbGpPWpGaD
Olopatadine—HRH1—epithelium—uterine cancer	0.00279	0.00593	CbGeAlD
Olopatadine—HRH1—uterine cervix—uterine cancer	0.00277	0.00587	CbGeAlD
Olopatadine—HRH1—smooth muscle tissue—uterine cancer	0.00269	0.00571	CbGeAlD
Olopatadine—HRH1—decidua—uterine cancer	0.00264	0.0056	CbGeAlD
Olopatadine—Urinary tract infection—Medroxyprogesterone Acetate—uterine cancer	0.00257	0.00643	CcSEcCtD
Olopatadine—Visual impairment—Progesterone—uterine cancer	0.00253	0.00631	CcSEcCtD
Olopatadine—S100A12—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—IRF1—uterine cancer	0.00251	0.0279	CbGpPWpGaD
Olopatadine—HRH1—endometrium—uterine cancer	0.00251	0.00531	CbGeAlD
Olopatadine—Epistaxis—Medroxyprogesterone Acetate—uterine cancer	0.0025	0.00624	CcSEcCtD
Olopatadine—Sinusitis—Medroxyprogesterone Acetate—uterine cancer	0.00248	0.0062	CcSEcCtD
Olopatadine—Eye disorder—Progesterone—uterine cancer	0.00245	0.00612	CcSEcCtD
Olopatadine—HRH1—mammalian vulva—uterine cancer	0.00242	0.00514	CbGeAlD
Olopatadine—S100A2—Direct p53 effectors—MET—uterine cancer	0.00238	0.0264	CbGpPWpGaD
Olopatadine—S100B—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—IRF1—uterine cancer	0.00237	0.0264	CbGpPWpGaD
Olopatadine—Immune system disorder—Progesterone—uterine cancer	0.00237	0.00592	CcSEcCtD
Olopatadine—Mediastinal disorder—Progesterone—uterine cancer	0.00236	0.0059	CcSEcCtD
Olopatadine—Pharyngitis—Medroxyprogesterone Acetate—uterine cancer	0.00236	0.00589	CcSEcCtD
Olopatadine—Keratitis—Epirubicin—uterine cancer	0.00231	0.00577	CcSEcCtD
Olopatadine—Visual impairment—Medroxyprogesterone Acetate—uterine cancer	0.00229	0.00572	CcSEcCtD
Olopatadine—Erythema—Progesterone—uterine cancer	0.00228	0.0057	CcSEcCtD
Olopatadine—S100A2—p73 transcription factor network—EP300—uterine cancer	0.00223	0.0248	CbGpPWpGaD
Olopatadine—Eye disorder—Medroxyprogesterone Acetate—uterine cancer	0.00222	0.00555	CcSEcCtD
Olopatadine—Back pain—Progesterone—uterine cancer	0.00221	0.00551	CcSEcCtD
Olopatadine—S100B—Nuclear signaling by ERBB4—ESR1—uterine cancer	0.00221	0.0245	CbGpPWpGaD
Olopatadine—Muscle spasms—Progesterone—uterine cancer	0.0022	0.00548	CcSEcCtD
Olopatadine—Vision blurred—Progesterone—uterine cancer	0.00215	0.00537	CcSEcCtD
Olopatadine—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00215	0.00536	CcSEcCtD
Olopatadine—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00214	0.00535	CcSEcCtD
Olopatadine—Keratitis—Doxorubicin—uterine cancer	0.00214	0.00534	CcSEcCtD
Olopatadine—Ill-defined disorder—Progesterone—uterine cancer	0.00212	0.00529	CcSEcCtD
Olopatadine—HRH1—female reproductive system—uterine cancer	0.00208	0.0044	CbGeAlD
Olopatadine—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.00207	0.00517	CcSEcCtD
Olopatadine—Malaise—Progesterone—uterine cancer	0.00206	0.00514	CcSEcCtD
Olopatadine—Dysgeusia—Medroxyprogesterone Acetate—uterine cancer	0.00203	0.00506	CcSEcCtD
Olopatadine—CYP3A4—renal system—uterine cancer	0.002	0.00425	CbGeAlD
Olopatadine—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.002	0.005	CcSEcCtD
Olopatadine—Cough—Progesterone—uterine cancer	0.00199	0.00498	CcSEcCtD
Olopatadine—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.00199	0.00497	CcSEcCtD
Olopatadine—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.00193	0.0215	CbGpPWpGaD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.00193	0.00482	CcSEcCtD
Olopatadine—Discomfort—Progesterone—uterine cancer	0.00192	0.0048	CcSEcCtD
Olopatadine—Ill-defined disorder—Medroxyprogesterone Acetate—uterine cancer	0.00192	0.00479	CcSEcCtD
Olopatadine—Dry mouth—Progesterone—uterine cancer	0.0019	0.00475	CcSEcCtD
Olopatadine—HRH1—female gonad—uterine cancer	0.00189	0.00401	CbGeAlD
Olopatadine—HRH1—vagina—uterine cancer	0.00188	0.00398	CbGeAlD
Olopatadine—Malaise—Medroxyprogesterone Acetate—uterine cancer	0.00187	0.00466	CcSEcCtD
Olopatadine—Oedema—Progesterone—uterine cancer	0.00186	0.00465	CcSEcCtD
Olopatadine—Infection—Progesterone—uterine cancer	0.00185	0.00462	CcSEcCtD
Olopatadine—Stinging—Epirubicin—uterine cancer	0.00185	0.00462	CcSEcCtD
Olopatadine—Pharyngitis—Dactinomycin—uterine cancer	0.00184	0.00459	CcSEcCtD
Olopatadine—Nervous system disorder—Progesterone—uterine cancer	0.00183	0.00456	CcSEcCtD
Olopatadine—Skin disorder—Progesterone—uterine cancer	0.00181	0.00452	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00175	0.00437	CcSEcCtD
Olopatadine—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00174	0.00435	CcSEcCtD
Olopatadine—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.00172	0.0043	CcSEcCtD
Olopatadine—Stinging—Doxorubicin—uterine cancer	0.00171	0.00427	CcSEcCtD
Olopatadine—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.00169	0.00422	CcSEcCtD
Olopatadine—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00168	0.00419	CcSEcCtD
Olopatadine—Dyspnoea—Progesterone—uterine cancer	0.00166	0.00415	CcSEcCtD
Olopatadine—Somnolence—Progesterone—uterine cancer	0.00166	0.00414	CcSEcCtD
Olopatadine—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00166	0.00413	CcSEcCtD
Olopatadine—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00164	0.0041	CcSEcCtD
Olopatadine—Cough increased—Epirubicin—uterine cancer	0.00164	0.00409	CcSEcCtD
Olopatadine—Lacrimation increased—Epirubicin—uterine cancer	0.00163	0.00406	CcSEcCtD
Olopatadine—Erythema—Dactinomycin—uterine cancer	0.00161	0.00403	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Progesterone—uterine cancer	0.00161	0.00402	CcSEcCtD
Olopatadine—Fatigue—Progesterone—uterine cancer	0.00161	0.00401	CcSEcCtD
Olopatadine—CYP3A4—female reproductive system—uterine cancer	0.00161	0.0034	CbGeAlD
Olopatadine—Pain—Progesterone—uterine cancer	0.00159	0.00398	CcSEcCtD
Olopatadine—Ulcer—Epirubicin—uterine cancer	0.00158	0.00395	CcSEcCtD
Olopatadine—Feeling abnormal—Progesterone—uterine cancer	0.00154	0.00383	CcSEcCtD
Olopatadine—Gastrointestinal pain—Progesterone—uterine cancer	0.00152	0.0038	CcSEcCtD
Olopatadine—Cough increased—Doxorubicin—uterine cancer	0.00151	0.00378	CcSEcCtD
Olopatadine—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00151	0.00376	CcSEcCtD
Olopatadine—Lacrimation increased—Doxorubicin—uterine cancer	0.0015	0.00375	CcSEcCtD
Olopatadine—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.0015	0.00375	CcSEcCtD
Olopatadine—Ill-defined disorder—Dactinomycin—uterine cancer	0.0015	0.00374	CcSEcCtD
Olopatadine—Infestation—Etoposide—uterine cancer	0.00149	0.00373	CcSEcCtD
Olopatadine—Infestation NOS—Etoposide—uterine cancer	0.00149	0.00373	CcSEcCtD
Olopatadine—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.00149	0.0165	CbGpPWpGaD
Olopatadine—S100A2—Direct p53 effectors—PTEN—uterine cancer	0.00148	0.0165	CbGpPWpGaD
Olopatadine—Dermatitis contact—Epirubicin—uterine cancer	0.00148	0.0037	CcSEcCtD
Olopatadine—Body temperature increased—Progesterone—uterine cancer	0.00147	0.00368	CcSEcCtD
Olopatadine—Abdominal pain—Progesterone—uterine cancer	0.00147	0.00368	CcSEcCtD
Olopatadine—Ulcer—Doxorubicin—uterine cancer	0.00147	0.00366	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00146	0.00364	CcSEcCtD
Olopatadine—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00146	0.00364	CcSEcCtD
Olopatadine—Malaise—Dactinomycin—uterine cancer	0.00146	0.00363	CcSEcCtD
Olopatadine—S100A2—Direct p53 effectors—EP300—uterine cancer	0.00141	0.0157	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—PGR—uterine cancer	0.00139	0.0155	CbGpPWpGaD
Olopatadine—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00139	0.00347	CcSEcCtD
Olopatadine—Dry eye—Epirubicin—uterine cancer	0.00138	0.00345	CcSEcCtD
Olopatadine—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00138	0.00345	CcSEcCtD
Olopatadine—Hypersensitivity—Progesterone—uterine cancer	0.00137	0.00343	CcSEcCtD
Olopatadine—Dermatitis contact—Doxorubicin—uterine cancer	0.00137	0.00342	CcSEcCtD
Olopatadine—Discomfort—Dactinomycin—uterine cancer	0.00136	0.00339	CcSEcCtD
Olopatadine—Asthenia—Progesterone—uterine cancer	0.00134	0.00334	CcSEcCtD
Olopatadine—Hypoaesthesia—Etoposide—uterine cancer	0.00134	0.00333	CcSEcCtD
Olopatadine—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00134	0.00333	CcSEcCtD
Olopatadine—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00134	0.00333	CcSEcCtD
Olopatadine—Pruritus—Progesterone—uterine cancer	0.00132	0.00329	CcSEcCtD
Olopatadine—Oedema—Dactinomycin—uterine cancer	0.00132	0.00329	CcSEcCtD
Olopatadine—Infection—Dactinomycin—uterine cancer	0.00131	0.00327	CcSEcCtD
Olopatadine—Dry eye—Doxorubicin—uterine cancer	0.00128	0.0032	CcSEcCtD
Olopatadine—Diarrhoea—Progesterone—uterine cancer	0.00128	0.00318	CcSEcCtD
Olopatadine—Eye disorder—Etoposide—uterine cancer	0.00125	0.00313	CcSEcCtD
Olopatadine—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00124	0.00311	CcSEcCtD
Olopatadine—Dizziness—Progesterone—uterine cancer	0.00123	0.00308	CcSEcCtD
Olopatadine—HRH1—lymph node—uterine cancer	0.00121	0.00257	CbGeAlD
Olopatadine—Immune system disorder—Etoposide—uterine cancer	0.00121	0.00303	CcSEcCtD
Olopatadine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00121	0.00303	CcSEcCtD
Olopatadine—Mediastinal disorder—Etoposide—uterine cancer	0.00121	0.00302	CcSEcCtD
Olopatadine—Eye pain—Epirubicin—uterine cancer	0.0012	0.00301	CcSEcCtD
Olopatadine—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00119	0.00298	CcSEcCtD
Olopatadine—Vomiting—Progesterone—uterine cancer	0.00118	0.00296	CcSEcCtD
Olopatadine—Rash—Progesterone—uterine cancer	0.00118	0.00293	CcSEcCtD
Olopatadine—Dermatitis—Progesterone—uterine cancer	0.00117	0.00293	CcSEcCtD
Olopatadine—Headache—Progesterone—uterine cancer	0.00117	0.00291	CcSEcCtD
Olopatadine—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00116	0.00288	CcSEcCtD
Olopatadine—Dysgeusia—Etoposide—uterine cancer	0.00114	0.00286	CcSEcCtD
Olopatadine—Fatigue—Dactinomycin—uterine cancer	0.00114	0.00284	CcSEcCtD
Olopatadine—Back pain—Etoposide—uterine cancer	0.00113	0.00282	CcSEcCtD
Olopatadine—Pain—Dactinomycin—uterine cancer	0.00113	0.00281	CcSEcCtD
Olopatadine—Muscle spasms—Etoposide—uterine cancer	0.00112	0.0028	CcSEcCtD
Olopatadine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00112	0.00279	CcSEcCtD
Olopatadine—Eye pain—Doxorubicin—uterine cancer	0.00111	0.00278	CcSEcCtD
Olopatadine—Nausea—Progesterone—uterine cancer	0.00111	0.00276	CcSEcCtD
Olopatadine—Feeling abnormal—Dactinomycin—uterine cancer	0.00109	0.00271	CcSEcCtD
Olopatadine—Ill-defined disorder—Etoposide—uterine cancer	0.00108	0.00271	CcSEcCtD
Olopatadine—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00108	0.00269	CcSEcCtD
Olopatadine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00107	0.00268	CcSEcCtD
Olopatadine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00106	0.00266	CcSEcCtD
Olopatadine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00106	0.00266	CcSEcCtD
Olopatadine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00106	0.00264	CcSEcCtD
Olopatadine—Malaise—Etoposide—uterine cancer	0.00105	0.00263	CcSEcCtD
Olopatadine—Abdominal pain—Dactinomycin—uterine cancer	0.00104	0.0026	CcSEcCtD
Olopatadine—Body temperature increased—Dactinomycin—uterine cancer	0.00104	0.0026	CcSEcCtD
Olopatadine—Cough—Etoposide—uterine cancer	0.00102	0.00255	CcSEcCtD
Olopatadine—S100A2—Direct p53 effectors—TP53—uterine cancer	0.00101	0.0112	CbGpPWpGaD
Olopatadine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.001	0.0025	CcSEcCtD
Olopatadine—Dry skin—Epirubicin—uterine cancer	0.000997	0.00249	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000988	0.00247	CcSEcCtD
Olopatadine—S100A12—Cytosolic sensors of pathogen-associated DNA—CTNNB1—uterine cancer	0.000984	0.0109	CbGpPWpGaD
Olopatadine—Discomfort—Etoposide—uterine cancer	0.000983	0.00245	CcSEcCtD
Olopatadine—Nasopharyngitis—Epirubicin—uterine cancer	0.000972	0.00243	CcSEcCtD
Olopatadine—Hypersensitivity—Dactinomycin—uterine cancer	0.000971	0.00242	CcSEcCtD
Olopatadine—Infection—Etoposide—uterine cancer	0.000947	0.00236	CcSEcCtD
Olopatadine—Asthenia—Dactinomycin—uterine cancer	0.000945	0.00236	CcSEcCtD
Olopatadine—Influenza—Epirubicin—uterine cancer	0.00094	0.00235	CcSEcCtD
Olopatadine—S100B—Cytosolic sensors of pathogen-associated DNA—CTNNB1—uterine cancer	0.00093	0.0103	CbGpPWpGaD
Olopatadine—Skin disorder—Etoposide—uterine cancer	0.000926	0.00231	CcSEcCtD
Olopatadine—Dry skin—Doxorubicin—uterine cancer	0.000922	0.0023	CcSEcCtD
Olopatadine—S100A12—Cytosolic sensors of pathogen-associated DNA—EP300—uterine cancer	0.000914	0.0102	CbGpPWpGaD
Olopatadine—Diarrhoea—Dactinomycin—uterine cancer	0.000901	0.00225	CcSEcCtD
Olopatadine—Nasopharyngitis—Doxorubicin—uterine cancer	0.0009	0.00225	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000873	0.00218	CcSEcCtD
Olopatadine—Influenza—Doxorubicin—uterine cancer	0.00087	0.00217	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—FGFR2—uterine cancer	0.000869	0.00965	CbGpPWpGaD
Olopatadine—S100B—Cytosolic sensors of pathogen-associated DNA—EP300—uterine cancer	0.000865	0.00961	CbGpPWpGaD
Olopatadine—Weight increased—Epirubicin—uterine cancer	0.000855	0.00214	CcSEcCtD
Olopatadine—Dyspnoea—Etoposide—uterine cancer	0.00085	0.00212	CcSEcCtD
Olopatadine—Somnolence—Etoposide—uterine cancer	0.000848	0.00212	CcSEcCtD
Olopatadine—Infestation—Epirubicin—uterine cancer	0.000838	0.00209	CcSEcCtD
Olopatadine—Infestation NOS—Epirubicin—uterine cancer	0.000838	0.00209	CcSEcCtD
Olopatadine—Vomiting—Dactinomycin—uterine cancer	0.000838	0.00209	CcSEcCtD
Olopatadine—Rash—Dactinomycin—uterine cancer	0.000831	0.00207	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000823	0.00205	CcSEcCtD
Olopatadine—Fatigue—Etoposide—uterine cancer	0.000822	0.00205	CcSEcCtD
Olopatadine—Pain—Etoposide—uterine cancer	0.000815	0.00204	CcSEcCtD
Olopatadine—Conjunctivitis—Epirubicin—uterine cancer	0.000815	0.00203	CcSEcCtD
Olopatadine—Urinary tract infection—Epirubicin—uterine cancer	0.000815	0.00203	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000808	0.00202	CcSEcCtD
Olopatadine—Weight increased—Doxorubicin—uterine cancer	0.000791	0.00198	CcSEcCtD
Olopatadine—Epistaxis—Epirubicin—uterine cancer	0.00079	0.00197	CcSEcCtD
Olopatadine—Sinusitis—Epirubicin—uterine cancer	0.000786	0.00196	CcSEcCtD
Olopatadine—Feeling abnormal—Etoposide—uterine cancer	0.000786	0.00196	CcSEcCtD
Olopatadine—S100A12—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—EP300—uterine cancer	0.000784	0.00871	CbGpPWpGaD
Olopatadine—Nausea—Dactinomycin—uterine cancer	0.000782	0.00195	CcSEcCtD
Olopatadine—Gastrointestinal pain—Etoposide—uterine cancer	0.00078	0.00195	CcSEcCtD
Olopatadine—Infestation NOS—Doxorubicin—uterine cancer	0.000775	0.00194	CcSEcCtD
Olopatadine—Infestation—Doxorubicin—uterine cancer	0.000775	0.00194	CcSEcCtD
Olopatadine—Rhinitis—Epirubicin—uterine cancer	0.000754	0.00188	CcSEcCtD
Olopatadine—Body temperature increased—Etoposide—uterine cancer	0.000754	0.00188	CcSEcCtD
Olopatadine—Abdominal pain—Etoposide—uterine cancer	0.000754	0.00188	CcSEcCtD
Olopatadine—Conjunctivitis—Doxorubicin—uterine cancer	0.000754	0.00188	CcSEcCtD
Olopatadine—Urinary tract infection—Doxorubicin—uterine cancer	0.000754	0.00188	CcSEcCtD
Olopatadine—Hypoaesthesia—Epirubicin—uterine cancer	0.000748	0.00187	CcSEcCtD
Olopatadine—Pharyngitis—Epirubicin—uterine cancer	0.000747	0.00186	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—ESR1—uterine cancer	0.000743	0.00826	CbGpPWpGaD
Olopatadine—S100B—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—EP300—uterine cancer	0.000741	0.00824	CbGpPWpGaD
Olopatadine—Epistaxis—Doxorubicin—uterine cancer	0.000731	0.00183	CcSEcCtD
Olopatadine—Sinusitis—Doxorubicin—uterine cancer	0.000727	0.00182	CcSEcCtD
Olopatadine—Visual impairment—Epirubicin—uterine cancer	0.000725	0.00181	CcSEcCtD
Olopatadine—Eye disorder—Epirubicin—uterine cancer	0.000703	0.00176	CcSEcCtD
Olopatadine—Hypersensitivity—Etoposide—uterine cancer	0.000702	0.00175	CcSEcCtD
Olopatadine—Rhinitis—Doxorubicin—uterine cancer	0.000698	0.00174	CcSEcCtD
Olopatadine—Hypoaesthesia—Doxorubicin—uterine cancer	0.000693	0.00173	CcSEcCtD
Olopatadine—Pharyngitis—Doxorubicin—uterine cancer	0.000691	0.00172	CcSEcCtD
Olopatadine—Asthenia—Etoposide—uterine cancer	0.000684	0.00171	CcSEcCtD
Olopatadine—Immune system disorder—Epirubicin—uterine cancer	0.000679	0.0017	CcSEcCtD
Olopatadine—Mediastinal disorder—Epirubicin—uterine cancer	0.000678	0.00169	CcSEcCtD
Olopatadine—Pruritus—Etoposide—uterine cancer	0.000675	0.00168	CcSEcCtD
Olopatadine—Visual impairment—Doxorubicin—uterine cancer	0.000671	0.00167	CcSEcCtD
Olopatadine—HRH1—IL-4 Signaling Pathway—SOCS3—uterine cancer	0.000666	0.0074	CbGpPWpGaD
Olopatadine—Erythema—Epirubicin—uterine cancer	0.000655	0.00163	CcSEcCtD
Olopatadine—Diarrhoea—Etoposide—uterine cancer	0.000652	0.00163	CcSEcCtD
Olopatadine—Eye disorder—Doxorubicin—uterine cancer	0.00065	0.00162	CcSEcCtD
Olopatadine—Dysgeusia—Epirubicin—uterine cancer	0.000641	0.0016	CcSEcCtD
Olopatadine—Back pain—Epirubicin—uterine cancer	0.000633	0.00158	CcSEcCtD
Olopatadine—Dizziness—Etoposide—uterine cancer	0.00063	0.00157	CcSEcCtD
Olopatadine—Muscle spasms—Epirubicin—uterine cancer	0.00063	0.00157	CcSEcCtD
Olopatadine—Immune system disorder—Doxorubicin—uterine cancer	0.000629	0.00157	CcSEcCtD
Olopatadine—Mediastinal disorder—Doxorubicin—uterine cancer	0.000627	0.00157	CcSEcCtD
Olopatadine—Vision blurred—Epirubicin—uterine cancer	0.000617	0.00154	CcSEcCtD
Olopatadine—Ill-defined disorder—Epirubicin—uterine cancer	0.000608	0.00152	CcSEcCtD
Olopatadine—Vomiting—Etoposide—uterine cancer	0.000606	0.00151	CcSEcCtD
Olopatadine—Erythema—Doxorubicin—uterine cancer	0.000606	0.00151	CcSEcCtD
Olopatadine—Rash—Etoposide—uterine cancer	0.000601	0.0015	CcSEcCtD
Olopatadine—Dermatitis—Etoposide—uterine cancer	0.000601	0.0015	CcSEcCtD
Olopatadine—Headache—Etoposide—uterine cancer	0.000597	0.00149	CcSEcCtD
Olopatadine—Dysgeusia—Doxorubicin—uterine cancer	0.000593	0.00148	CcSEcCtD
Olopatadine—Malaise—Epirubicin—uterine cancer	0.000591	0.00147	CcSEcCtD
Olopatadine—Back pain—Doxorubicin—uterine cancer	0.000586	0.00146	CcSEcCtD
Olopatadine—Muscle spasms—Doxorubicin—uterine cancer	0.000583	0.00145	CcSEcCtD
Olopatadine—Cough—Epirubicin—uterine cancer	0.000571	0.00143	CcSEcCtD
Olopatadine—Vision blurred—Doxorubicin—uterine cancer	0.000571	0.00143	CcSEcCtD
Olopatadine—Nausea—Etoposide—uterine cancer	0.000566	0.00141	CcSEcCtD
Olopatadine—Ill-defined disorder—Doxorubicin—uterine cancer	0.000562	0.0014	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000554	0.00138	CcSEcCtD
Olopatadine—Discomfort—Epirubicin—uterine cancer	0.000551	0.00138	CcSEcCtD
Olopatadine—HRH1—IL-4 Signaling Pathway—BIRC5—uterine cancer	0.00055	0.00611	CbGpPWpGaD
Olopatadine—Malaise—Doxorubicin—uterine cancer	0.000546	0.00136	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—ERBB2—uterine cancer	0.000545	0.00606	CbGpPWpGaD
Olopatadine—Dry mouth—Epirubicin—uterine cancer	0.000545	0.00136	CcSEcCtD
Olopatadine—Oedema—Epirubicin—uterine cancer	0.000534	0.00133	CcSEcCtD
Olopatadine—Infection—Epirubicin—uterine cancer	0.000531	0.00133	CcSEcCtD
Olopatadine—Cough—Doxorubicin—uterine cancer	0.000529	0.00132	CcSEcCtD
Olopatadine—Nervous system disorder—Epirubicin—uterine cancer	0.000524	0.00131	CcSEcCtD
Olopatadine—Skin disorder—Epirubicin—uterine cancer	0.000519	0.0013	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—IRF1—uterine cancer	0.000517	0.00574	CbGpPWpGaD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000512	0.00128	CcSEcCtD
Olopatadine—Discomfort—Doxorubicin—uterine cancer	0.00051	0.00127	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—CDKN1B—uterine cancer	0.000505	0.00561	CbGpPWpGaD
Olopatadine—Dry mouth—Doxorubicin—uterine cancer	0.000504	0.00126	CcSEcCtD
Olopatadine—Oedema—Doxorubicin—uterine cancer	0.000494	0.00123	CcSEcCtD
Olopatadine—Infection—Doxorubicin—uterine cancer	0.000491	0.00123	CcSEcCtD
Olopatadine—S100B—Innate Immune System—IRF1—uterine cancer	0.000489	0.00543	CbGpPWpGaD
Olopatadine—Nervous system disorder—Doxorubicin—uterine cancer	0.000485	0.00121	CcSEcCtD
Olopatadine—Skin disorder—Doxorubicin—uterine cancer	0.00048	0.0012	CcSEcCtD
Olopatadine—Dyspnoea—Epirubicin—uterine cancer	0.000476	0.00119	CcSEcCtD
Olopatadine—Somnolence—Epirubicin—uterine cancer	0.000475	0.00119	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—PTEN—uterine cancer	0.000465	0.00517	CbGpPWpGaD
Olopatadine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000461	0.00115	CcSEcCtD
Olopatadine—Fatigue—Epirubicin—uterine cancer	0.000461	0.00115	CcSEcCtD
Olopatadine—Pain—Epirubicin—uterine cancer	0.000457	0.00114	CcSEcCtD
Olopatadine—Dyspnoea—Doxorubicin—uterine cancer	0.000441	0.0011	CcSEcCtD
Olopatadine—Feeling abnormal—Epirubicin—uterine cancer	0.00044	0.0011	CcSEcCtD
Olopatadine—Somnolence—Doxorubicin—uterine cancer	0.00044	0.0011	CcSEcCtD
Olopatadine—Gastrointestinal pain—Epirubicin—uterine cancer	0.000437	0.00109	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000427	0.00107	CcSEcCtD
Olopatadine—Fatigue—Doxorubicin—uterine cancer	0.000426	0.00106	CcSEcCtD
Olopatadine—Pain—Doxorubicin—uterine cancer	0.000423	0.00106	CcSEcCtD
Olopatadine—Abdominal pain—Epirubicin—uterine cancer	0.000422	0.00105	CcSEcCtD
Olopatadine—Body temperature increased—Epirubicin—uterine cancer	0.000422	0.00105	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—NRAS—uterine cancer	0.000415	0.00461	CbGpPWpGaD
Olopatadine—Feeling abnormal—Doxorubicin—uterine cancer	0.000407	0.00102	CcSEcCtD
Olopatadine—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000404	0.00101	CcSEcCtD
Olopatadine—Hypersensitivity—Epirubicin—uterine cancer	0.000394	0.000983	CcSEcCtD
Olopatadine—Abdominal pain—Doxorubicin—uterine cancer	0.000391	0.000976	CcSEcCtD
Olopatadine—Body temperature increased—Doxorubicin—uterine cancer	0.000391	0.000976	CcSEcCtD
Olopatadine—Asthenia—Epirubicin—uterine cancer	0.000383	0.000957	CcSEcCtD
Olopatadine—Pruritus—Epirubicin—uterine cancer	0.000378	0.000944	CcSEcCtD
Olopatadine—Diarrhoea—Epirubicin—uterine cancer	0.000366	0.000913	CcSEcCtD
Olopatadine—Hypersensitivity—Doxorubicin—uterine cancer	0.000364	0.00091	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—KRAS—uterine cancer	0.000357	0.00397	CbGpPWpGaD
Olopatadine—Asthenia—Doxorubicin—uterine cancer	0.000355	0.000886	CcSEcCtD
Olopatadine—Dizziness—Epirubicin—uterine cancer	0.000353	0.000882	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—AKR1B10—uterine cancer	0.000352	0.00391	CbGpPWpGaD
Olopatadine—Pruritus—Doxorubicin—uterine cancer	0.00035	0.000873	CcSEcCtD
Olopatadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000345	0.00383	CbGpPWpGaD
Olopatadine—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000341	0.00378	CbGpPWpGaD
Olopatadine—Vomiting—Epirubicin—uterine cancer	0.00034	0.000848	CcSEcCtD
Olopatadine—Diarrhoea—Doxorubicin—uterine cancer	0.000338	0.000845	CcSEcCtD
Olopatadine—Rash—Epirubicin—uterine cancer	0.000337	0.000841	CcSEcCtD
Olopatadine—Dermatitis—Epirubicin—uterine cancer	0.000337	0.000841	CcSEcCtD
Olopatadine—Headache—Epirubicin—uterine cancer	0.000335	0.000836	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—PIK3CA—uterine cancer	0.000328	0.00365	CbGpPWpGaD
Olopatadine—Dizziness—Doxorubicin—uterine cancer	0.000327	0.000816	CcSEcCtD
Olopatadine—Nausea—Epirubicin—uterine cancer	0.000317	0.000793	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—FGFR2—uterine cancer	0.000316	0.00351	CbGpPWpGaD
Olopatadine—Vomiting—Doxorubicin—uterine cancer	0.000314	0.000785	CcSEcCtD
Olopatadine—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	0.000314	0.00349	CbGpPWpGaD
Olopatadine—Rash—Doxorubicin—uterine cancer	0.000312	0.000778	CcSEcCtD
Olopatadine—Dermatitis—Doxorubicin—uterine cancer	0.000311	0.000778	CcSEcCtD
Olopatadine—Headache—Doxorubicin—uterine cancer	0.00031	0.000773	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—HRAS—uterine cancer	0.000304	0.00337	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IRF1—uterine cancer	0.000301	0.00334	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—FGFR2—uterine cancer	0.000299	0.00332	CbGpPWpGaD
Olopatadine—Nausea—Doxorubicin—uterine cancer	0.000294	0.000733	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—RNF43—uterine cancer	0.000292	0.00324	CbGpPWpGaD
Olopatadine—S100B—Immune System—IRF1—uterine cancer	0.000285	0.00316	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—EP300—uterine cancer	0.000284	0.00315	CbGpPWpGaD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.00028	0.00311	CbGpPWpGaD
Olopatadine—S100A12—Immune System—FBXW7—uterine cancer	0.00027	0.003	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—AKT1—uterine cancer	0.000268	0.00298	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—INHBA—uterine cancer	0.000267	0.00297	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	0.000264	0.00293	CbGpPWpGaD
Olopatadine—S100B—Immune System—FBXW7—uterine cancer	0.000255	0.00283	CbGpPWpGaD
Olopatadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000254	0.00282	CbGpPWpGaD
Olopatadine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000251	0.00278	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	0.000245	0.00272	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—AKR1C1—uterine cancer	0.00024	0.00267	CbGpPWpGaD
Olopatadine—S100A12—Immune System—SOCS3—uterine cancer	0.000221	0.00245	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—PIK3CA—uterine cancer	0.00021	0.00233	CbGpPWpGaD
Olopatadine—S100B—Immune System—SOCS3—uterine cancer	0.000209	0.00232	CbGpPWpGaD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000206	0.00229	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—ERBB2—uterine cancer	0.000198	0.0022	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—ERBB2—uterine cancer	0.000188	0.00208	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—AKR1C3—uterine cancer	0.000185	0.00206	CbGpPWpGaD
Olopatadine—S100A12—Immune System—FGFR2—uterine cancer	0.000184	0.00205	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—CDKN1B—uterine cancer	0.000184	0.00204	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PGR—uterine cancer	0.00018	0.002	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	0.00018	0.002	CbGpPWpGaD
Olopatadine—S100B—Immune System—FGFR2—uterine cancer	0.000174	0.00193	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—CDKN1B—uterine cancer	0.000174	0.00193	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—CTNNB1—uterine cancer	0.000174	0.00193	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—YWHAE—uterine cancer	0.000172	0.00191	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—AKT1—uterine cancer	0.000171	0.0019	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—PTEN—uterine cancer	0.000169	0.00188	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—FBXW7—uterine cancer	0.000165	0.00183	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—CTNNB1—uterine cancer	0.000164	0.00182	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—EP300—uterine cancer	0.000161	0.00179	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—PTEN—uterine cancer	0.00016	0.00178	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	0.000158	0.00175	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—EP300—uterine cancer	0.000153	0.0017	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—NRAS—uterine cancer	0.000151	0.00168	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	0.000149	0.00165	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	0.000147	0.00163	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—STK11—uterine cancer	0.000144	0.0016	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—NRAS—uterine cancer	0.000143	0.00159	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	0.000138	0.00154	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CDH1—uterine cancer	0.000137	0.00152	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—SOCS3—uterine cancer	0.000135	0.0015	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—KRAS—uterine cancer	0.00013	0.00144	CbGpPWpGaD
Olopatadine—S100B—Immune System—CDH1—uterine cancer	0.00013	0.00144	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CDKN2B—uterine cancer	0.000129	0.00144	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IGF1R—uterine cancer	0.000125	0.00139	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—KRAS—uterine cancer	0.000123	0.00137	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—PIK3CA—uterine cancer	0.000119	0.00133	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—SMAD3—uterine cancer	0.000118	0.00131	CbGpPWpGaD
Olopatadine—S100A12—Immune System—ERBB2—uterine cancer	0.000116	0.00128	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—PIK3CA—uterine cancer	0.000113	0.00125	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—FGFR2—uterine cancer	0.000113	0.00125	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—HRAS—uterine cancer	0.00011	0.00123	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	0.000109	0.00121	CbGpPWpGaD
Olopatadine—S100B—Immune System—ERBB2—uterine cancer	0.000109	0.00121	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	0.000108	0.0012	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CDKN1B—uterine cancer	0.000107	0.00119	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—HRAS—uterine cancer	0.000104	0.00116	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000103	0.00114	CbGpPWpGaD
Olopatadine—S100B—Immune System—CDKN1B—uterine cancer	0.000101	0.00112	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CTNNB1—uterine cancer	0.000101	0.00112	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PTEN—uterine cancer	9.86e-05	0.0011	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AKR1B10—uterine cancer	9.84e-05	0.00109	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—AKT1—uterine cancer	9.75e-05	0.00108	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ESR1—uterine cancer	9.63e-05	0.00107	CbGpPWpGaD
Olopatadine—S100B—Immune System—CTNNB1—uterine cancer	9.56e-05	0.00106	CbGpPWpGaD
Olopatadine—S100A12—Immune System—EP300—uterine cancer	9.4e-05	0.00104	CbGpPWpGaD
Olopatadine—S100B—Immune System—PTEN—uterine cancer	9.32e-05	0.00104	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—AKT1—uterine cancer	9.22e-05	0.00102	CbGpPWpGaD
Olopatadine—S100B—Immune System—EP300—uterine cancer	8.89e-05	0.000988	CbGpPWpGaD
Olopatadine—S100A12—Immune System—NRAS—uterine cancer	8.79e-05	0.000977	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	8.78e-05	0.000976	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CCL2—uterine cancer	8.48e-05	0.000942	CbGpPWpGaD
Olopatadine—S100B—Immune System—NRAS—uterine cancer	8.31e-05	0.000924	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—RNF43—uterine cancer	8.15e-05	0.000906	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	8.11e-05	0.000901	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CCL2—uterine cancer	7.81e-05	0.000868	CbGpPWpGaD
Olopatadine—HRH1—G alpha (q) signalling events—PIK3CA—uterine cancer	7.76e-05	0.000863	CbGpPWpGaD
Olopatadine—S100A12—Immune System—KRAS—uterine cancer	7.57e-05	0.000841	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	7.56e-05	0.00084	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—INHBA—uterine cancer	7.45e-05	0.000828	CbGpPWpGaD
Olopatadine—S100B—Immune System—KRAS—uterine cancer	7.16e-05	0.000795	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ERBB2—uterine cancer	7.07e-05	0.000785	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PIK3CA—uterine cancer	6.95e-05	0.000773	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	6.94e-05	0.000772	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AKR1C1—uterine cancer	6.71e-05	0.000746	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CXCL8—uterine cancer	6.7e-05	0.000745	CbGpPWpGaD
Olopatadine—S100B—Immune System—PIK3CA—uterine cancer	6.57e-05	0.000731	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CDKN1B—uterine cancer	6.54e-05	0.000727	CbGpPWpGaD
Olopatadine—S100A12—Immune System—HRAS—uterine cancer	6.43e-05	0.000715	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	6.43e-05	0.000714	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CTNNB1—uterine cancer	6.18e-05	0.000687	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CXCL8—uterine cancer	6.17e-05	0.000686	CbGpPWpGaD
Olopatadine—S100B—Immune System—HRAS—uterine cancer	6.08e-05	0.000676	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PTEN—uterine cancer	6.03e-05	0.00067	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SRD5A2—uterine cancer	5.88e-05	0.000653	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NDUFB11—uterine cancer	5.88e-05	0.000653	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EP300—uterine cancer	5.75e-05	0.000639	CbGpPWpGaD
Olopatadine—S100A12—Immune System—AKT1—uterine cancer	5.68e-05	0.000631	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—VEGFA—uterine cancer	5.44e-05	0.000605	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NRAS—uterine cancer	5.38e-05	0.000597	CbGpPWpGaD
Olopatadine—S100B—Immune System—AKT1—uterine cancer	5.37e-05	0.000597	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AKR1C3—uterine cancer	5.17e-05	0.000574	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PGR—uterine cancer	5.04e-05	0.00056	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—YWHAE—uterine cancer	4.8e-05	0.000534	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—KRAS—uterine cancer	4.63e-05	0.000514	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FBXW7—uterine cancer	4.61e-05	0.000512	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PIK3CA—uterine cancer	4.25e-05	0.000472	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AKR1B1—uterine cancer	4.25e-05	0.000472	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—STAR—uterine cancer	4.25e-05	0.000472	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TP53—uterine cancer	4.11e-05	0.000457	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—STK11—uterine cancer	4.03e-05	0.000447	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CCL2—uterine cancer	4.01e-05	0.000445	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—HRAS—uterine cancer	3.93e-05	0.000437	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SOCS3—uterine cancer	3.77e-05	0.000419	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CDKN2B—uterine cancer	3.61e-05	0.000401	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IGF1R—uterine cancer	3.5e-05	0.000389	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CXCL8—uterine cancer	3.49e-05	0.000388	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—AKT1—uterine cancer	3.47e-05	0.000386	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—POLD1—uterine cancer	3.33e-05	0.00037	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SMAD3—uterine cancer	3.29e-05	0.000366	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CXCL8—uterine cancer	3.17e-05	0.000352	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FGFR2—uterine cancer	3.14e-05	0.000349	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AKR1C1—uterine cancer	3.12e-05	0.000346	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—RRM2—uterine cancer	2.78e-05	0.000309	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—DCN—uterine cancer	2.7e-05	0.0003	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ESR1—uterine cancer	2.69e-05	0.000299	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.54e-05	0.000282	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—NRAS—uterine cancer	2.54e-05	0.000282	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.4e-05	0.000267	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCL2—uterine cancer	2.37e-05	0.000263	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CA—uterine cancer	2.21e-05	0.000246	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—KRAS—uterine cancer	2.19e-05	0.000243	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CA—uterine cancer	2.01e-05	0.000223	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ERBB2—uterine cancer	1.97e-05	0.000219	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CXCL8—uterine cancer	1.87e-05	0.000208	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—STK11—uterine cancer	1.87e-05	0.000208	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.87e-05	0.000208	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—HRAS—uterine cancer	1.86e-05	0.000207	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CDKN1B—uterine cancer	1.83e-05	0.000203	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—AKT1—uterine cancer	1.81e-05	0.000201	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CTNNB1—uterine cancer	1.73e-05	0.000192	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTEN—uterine cancer	1.68e-05	0.000187	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—AKT1—uterine cancer	1.64e-05	0.000182	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EP300—uterine cancer	1.6e-05	0.000178	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—VEGFA—uterine cancer	1.52e-05	0.000169	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NRAS—uterine cancer	1.5e-05	0.000167	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MTHFR—uterine cancer	1.41e-05	0.000156	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KRAS—uterine cancer	1.29e-05	0.000144	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CA—uterine cancer	1.19e-05	0.000132	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TP53—uterine cancer	1.15e-05	0.000128	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HRAS—uterine cancer	1.1e-05	0.000122	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AKT1—uterine cancer	9.7e-06	0.000108	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PTEN—uterine cancer	7.82e-06	8.69e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—EP300—uterine cancer	7.45e-06	8.28e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CA—uterine cancer	5.51e-06	6.13e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AKT1—uterine cancer	4.51e-06	5.01e-05	CbGpPWpGaD
